Patient description: 19 yo Hispanic female G1P1 at 32+ 6 weeks of gestational age presented to the OB clinic for routine follow up complaining of mild headache and leg swelling. Primary evaluation revealed BP of 146/99 and urine dipstick with 3+ proteins. Her BP and U/A were normal in previous visit. Repeat BP a few hours later is 150/100 mmHg. Laboratory studies showed a normal hematocrit, platelet count, and liver transaminase levels. She is complaining of fatigue but no fever or chills. She is also suffering of headaches with no vision changes. No shortness of breath, cough, chest pain, orthopnea and palpitations or skin rash were observed. Her physical exam was negative for abdominal pain, change in bowel habits, nausea, vomiting, dysuria, frequency, hematuria or frothy urine. Leg swelling was observed with no arthralgia or back pain. She has no specific past medical issues and only uses prenatal vitamins. Her family history is positive for DM type 2 and HTN. She is a social alcohol consumer with the negative history of smoking or drug use. She is only have one partner in past 2 years and didn't have any contraceptive methods since 2 years ago. Her BMI was 24 at the first

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  ALK-Positive Large B-Cell Lymphoma Burkitt-Like Lymphoma With 11q Aberration Diffuse Large B-Cell Lymphoma Activated B-Cell Type Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type Diffuse Large B-Cell Lymphoma, Not Otherwise Specified EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified EBV-Positive Mucocutaneous Ulcer HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements High Grade B-Cell Lymphoma, Not Otherwise Specified Intravascular Large B-Cell Lymphoma Large B-Cell Lymphoma With IRF4 Rearrangement Plasmablastic Lymphoma Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System Primary Effusion Lymphoma Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma Recurrent B-Cell Non-Hodgkin Lymphoma Recurrent Burkitt Lymphoma Recurrent Diffuse Large B-Cell Lymphoma Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements Recurrent Lymphomatoid Granulomatosis Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma Refractory B-Cell Non-Hodgkin Lymphoma Refractory Burkitt Lymphoma Refractory Diffuse Large B-Cell Lymphoma Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Patients must have a histopathologically confirmed diagnosis of an aggressive B-cell non-Hodgkin lymphoma that is recurrent or refractory to standard therapy For the purpose of this study, aggressive B-cell NHL will be deemed any lymphoma belonging to one of the following groups according to the 2016 revision of the World Health Organization (WHO) classification of lymphoid neoplasms For the purposes of stratification, diagnoses are grouped into 2 categories Category A Burkitt lymphoma Burkitt-like lymphoma with 11q aberration High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements High-grade B-cell lymphoma, not otherwise specified (NOS) Category B Diffuse large B-cell lymphoma (DLBCL), NOS  Patient has received chemotherapy, targeted agent, or radiotherapy within 4 weeks or at least 5 half-lives, whichever is longer, prior to registration Palliative (limited-field) radiation therapy is permitted, if all of the following are met Repeat imaging demonstrates no new sites of bone metastases The lesion being considered for palliative radiation is not a target lesion Patient has received immunotherapy (including monoclonal antibodies) within 4 weeks prior to registration Patients who have not recovered to grade 1 or less from any adverse events due to agents administered more than 4 weeks earlier (excluding alopecia) Patients who are receiving any other investigational agents Patients should be excluded if they have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways Patients who have received autologous stem cell transplant (ASCT) =< 12 weeks prior to the first dose of study drug Patients with a prior history of allogeneic stem cell or solid organ transplantation